1DR9|pdb_00001dr9
CRYSTAL STRUCTURE OF A SOLUBLE FORM OF B7-1 (CD80)
- PDB DOI: https://doi.org/10.2210/pdb1DR9/pdb
- Classification: IMMUNE SYSTEM
- Organism(s): Homo sapiens
- Expression System: Escherichia coli
- Mutation(s): Yes
- Deposited: 2000-01-06 Released: 2000-01-10
- Deposition Author(s): Ikemizu, S.,Jones, E.Y.,Stuart, D.I.,Davis, S.J.
Experimental Data Snapshot
- Method: X-RAY DIFFRACTION
- Resolution: 3.00 Å
- R-Value Free: 0.280 (Depositor)
- R-Value Work: 0.238 (Depositor)
- R-Value Observed: 0.238 (Depositor)
wwPDB Validation 3D Report Full Report
Download MendeleyStructure and dimerization of a soluble form of B7-1.
Ikemizu, S., Gilbert, R.J., Fennelly, J.A., Collins, A.V., Harlos, K., Jones, E.Y., Stuart, D.I., Davis, S.J.(2000) Immunity 12: 51-60
- PubMed: 10661405 Search on PubMed
- DOI: https://doi.org/10.1016/s1074-7613(00)80158-2
- Primary Citation of Related Structures:
1DR9 - PubMed Abstract:
B7-1 (CD80) and B7-2 (CD86) are glycoproteins expressed on antigen-presenting cells. The binding of these molecules to the T cell homodimers CD28 and CTLA-4 (CD152) generates costimulatory and inhibitory signals in T cells, respectively. The crystal structure of the extracellular region of B7-1 (sB7-1), solved to 3 A resolution, consists of a novel combination of two Ig-like domains, one characteristic of adhesion molecules and the other previously seen only in antigen receptors. In the crystal lattice, sB7-1 unexpectedly forms parallel, 2-fold rotationally symmetric homodimers. Analytical ultracentrifugation reveals that sB7-1 also dimerizes in solution. The structural data suggest a mechanism whereby the avidity-enhanced binding of B7-1 and CTLA-4 homodimers, along with the relatively high affinity of these interactions, favors the formation of very stable inhibitory signaling complexes.
Organizational Affiliation:
Division of Structural Biology, Wellcome Trust Centre for Human Genetics, The University of Oxford, United Kingdom.
Explore in 3D: Structure |Sequence Annotations |Validation Report |Ligand Interaction (NAG)
Global Symmetry: Asymmetric - C1
Global Stoichiometry: Monomer - A1
Find Similar Assemblies
Biological assembly 1 assigned by authors.
Macromolecule Content
- Total Structure Weight: 23.66 kDa
- Atom Count: 1,645
- Modelled Residue Count: 200
- Deposited Residue Count: 201
- Unique protein chains: 1
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| T LYMPHOCYTE ACTIVATION ANTIGEN | 201 | Homo sapiens | Mutation(s): 1 Gene Names: CHO |  | |
UniProt & NIH Common Fund Data Resources | |||||
Find proteins for P33681 (Homo sapiens) Explore P33681 Go to UniProtKB: P33681 | |||||
PHAROS: P33681 GTEx: ENSG00000121594 | |||||
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | P33681 | ||||
Glycosylation | |||||
| Glycosylation Sites: 3 | Go to GlyGen: P33681-1 | ||||
Sequence AnnotationsExpand | |||||
| |||||
| Ligands 1 Unique | |||||
|---|---|---|---|---|---|
| ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
| NAG Query on NAG Download Ideal Coordinates CCD File | B [auth A], C [auth A], D [auth A] | 2-acetamido-2-deoxy-beta-D-glucopyranose C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N |  | ||
Experimental Data
- Method: X-RAY DIFFRACTION
- Resolution: 3.00 Å
- R-Value Free: 0.280 (Depositor)
- R-Value Work: 0.238 (Depositor)
- R-Value Observed: 0.238 (Depositor)
| Length ( Å ) | Angle ( ˚ ) |
|---|---|
| a = 57.28 | α = 90 |
| b = 57.28 | β = 90 |
| c = 298.93 | γ = 90 |
| Software Name | Purpose |
|---|---|
| DENZO | data reduction |
| SCALEPACK | data scaling |
| SOLVE | phasing |
| CNS | refinement |
Deposition Data
- Released Date: 2000-01-10 Deposition Author(s): Ikemizu, S.,Jones, E.Y.,Stuart, D.I.,Davis, S.J.
Revision History (Full details and data files)
- Version 1.0: 2000-01-10
Type: Initial release - Version 1.1: 2008-04-27
Changes: Version format compliance - Version 1.2: 2011-07-13
Changes: Non-polymer description, Version format compliance - Version 1.3: 2018-01-31
Changes: Experimental preparation - Version 1.4: 2020-07-29
Type: Remediation
Reason: Carbohydrate remediation
Changes: Data collection, Derived calculations, Structure summary - Version 1.5: 2021-11-03
Changes: Database references, Structure summary - Version 1.6: 2024-10-16
Changes: Data collection, Structure summary
RCSB PDB is hosted by
RCSB PDB is a member of the
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729.